Sinopharm Group's H1 Profit Declines 10% as Revenue Drops

MT Newswires Live
2024/09/25

Sinopharm Group (HKG:1099) reported a net profit attributable to the parent of 3.70 billion yuan for the first six months ended June 30, a 9.76% decline compared with the 4.10 billion yuan profit reported in the year-ago period, according to the company's interim report filed with the Hong Kong bourse Wednesday.

Earnings per share were 1.19 yuan per share, down from 1.32 yuan per share a year earlier.

Revenue of the pharmaceutical company fell to 294.73 billion yuan from 300.95 billion yuan in the prior-year period

Price (HKD): $17.98, Change: $+0.74, Percent Change: +4.29%

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10